Ultragenyx Stock Surges on Historic FDA Approval for Sanfilippo Syndrome

Key Facts

1Ultragenyx Pharmaceutical shares rose after hours following FDA approval of its new treatment.

2FAYUVI is the first-ever approved treatment for Sanfilippo syndrome Type A.

In a move reflecting the accelerating pace of biotech innovation for rare diseases, Ultragenyx Pharmaceutical shares surged in after-hours trading. This momentum follows the company's announcement that its new drug, FAYUVI, received approval from the U.S. Food and Drug Administration (FDA). FAYUVI stands as the first-ever approved treatment for Sanfilippo syndrome Type A, marking a pivotal shift in the therapeutic landscape for this condition.

Per market data, RARE shares closed at $14.50 on September 17, 2026, prior to the approval news that catalyzed the after-hours move. During that session, the stock traded between a low of $13.20 and a high of $14.58. This regulatory milestone strengthens the company's competitive positioning within the specialized pharmaceutical market, particularly as the treatment is a first-in-class therapy.

Looking ahead, investors are monitoring the official market response at the next opening to confirm support levels above the September 17 close of $14.50. With no immediate sector-specific catalysts in the upcoming economic calendar, focus remains on the company's commercialization plans for FAYUVI. Traders also continue to watch broader U.S. inflation trends which may influence risk appetite across the high-growth biotech sector.